Beijing Science Sun Pharmaceutical Co., Ltd.
XSEC:300485 Stock Report
Beijing Science Sun Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6 Beijing Science Sun Pharmaceutical has a total shareholder equity of CN¥3.4B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥3.5B and CN¥163.4M respectively.
Key information Interest coverage ratio n/a Cash CN¥1.53b Equity CN¥3.35b Total liabilities CN¥163.36m Total assets CN¥3.52b
Recent financial health updates
Show all updates
Third quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.12 loss in 3Q 2023) Oct 25
Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Sep 30
Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.52 in 2Q 2023) Aug 28
Beijing Science Sun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Jun 29
Dividend reduced to CN¥0.022 May 25
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 May 25
First quarter 2024 earnings released: CN¥0.40 loss per share (vs CN¥0.002 profit in 1Q 2023) Apr 26
Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 30, 2024 Apr 10
Full year 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.43 in FY 2022) Apr 10
Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Mar 30
Investor sentiment deteriorates as stock falls 17% Feb 02
Insufficient new directors Feb 01
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes Jan 30
Beijing Science Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024 Dec 30
Third quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.037 profit in 3Q 2022) Oct 27
Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.27 in 2Q 2022) Aug 25
Beijing Science Sun Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023 May 17
First quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.22 in 1Q 2022) Apr 26
Investor sentiment improved over the past week Dec 12
Third quarter 2022 earnings released: EPS: CN¥0.037 (vs CN¥0.11 in 3Q 2021) Oct 27
Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.09 in 2Q 2021) Aug 27
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Cash Dividend for the Fiscal Year 2021, Payable on 31 May 2022 May 27
First quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.09 in 1Q 2021) Apr 30
Beijing Science Sun Pharmaceutical Co., Ltd. Approves the Profit Distribution of Final Cash Dividend for the Year 2021 Apr 24
Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2022 Apr 02
Full year 2021 earnings released: EPS: CN¥0.84 (vs CN¥0.32 in FY 2020) Apr 02
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021 Apr 01
Investor sentiment improved over the past week Mar 16
Investor sentiment improved over the past week Jan 19
Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.09 in 3Q 2020) Oct 28
Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.14 in 2Q 2020) Aug 28
Investor sentiment improved over the past week Aug 04
Upcoming dividend of CN¥0.065 per share May 03
First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.05 in 1Q 2020) Apr 29
Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.31 in FY 2019) Mar 30
New 90-day low: CN¥11.30 Mar 13
Full year 2020 earnings released: EPS CN¥0.31 (vs CN¥0.31 in FY 2019) Mar 06
Beijing Science Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021 Feb 24
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Directorate Changes Jan 31
New 90-day low: CN¥12.45 Jan 28
New 90-day low: CN¥13.92 Jan 07
New 90-day low: CN¥16.02 Dec 12
Third quarter earnings released Oct 28
Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020 Oct 20
New 90-day low - CN¥16.09 Sep 10
First half earnings released Aug 29
Beijing Science Sun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Aug 13
Financial Position Analysis
Short Term Liabilities: 300485's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥83.1M).
Long Term Liabilities: 300485's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥80.3M).
Debt to Equity History and Analysis
Debt Level: 300485 is debt free.
Reducing Debt: 300485 has not had any debt for past 5 years.
Debt Coverage: 300485 has no debt, therefore it does not need to be covered by operating cash flow .
Interest Coverage: 300485 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}